株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

大腸癌治療薬のアジア太平洋地域市場:2015年〜2019年

Colorectal Cancer Therapeutics Market in APAC 2015-2019

発行 TechNavio (Infiniti Research Ltd.) 商品コード 347445
出版日 ページ情報 英文 106 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.58円で換算しております。
Back to Top
大腸癌治療薬のアジア太平洋地域市場:2015年〜2019年 Colorectal Cancer Therapeutics Market in APAC 2015-2019
出版日: 2015年12月16日 ページ情報: 英文 106 Pages
概要

アジア太平洋地域の大腸癌治療薬市場は、2014年〜2019年のCAGRで、6.32%の成長が見込まれています。

当レポートでは、アジア太平洋地域の大腸癌治療薬市場について調査分析し、市場規模と成長率、市場動向、市場促進要因・課題、市場機会について検証するほか、主要ベンダーなどについて、体系的な情報を提供しています。

第1章 エグゼクティブサマリー

第2章 調査範囲

  • 市場概要
  • 主要ベンダー製品
  • Vectibix

第3章 製品プロファイル

  • Stivarga
  • Erbitux
  • Xeloda
  • Avastin
  • Zaltrap

第4章 市場調査手法

  • 調査手法
  • 経済指標

第5章 イントロダクション

  • 主な市場ハイライト

第6章 疾患の概要

  • 疾患の理解
  • 高い危険因子
  • 兆候と症状
  • 病態生理
  • 診断
  • 病期
  • バイオマーカー検査
  • 疫学
  • 治療

第7章 パイプラインのポートフォリオ

  • パイプライン候補に関する情報

第8章 市場情勢

  • 市場概要
  • 市場規模と予測
  • 日本市場
  • 中国市場
  • ファイブフォース分析

第9章 市場区分:分子タイプ別

  • 小分子
  • 生物製剤

第10章 市場区分:投与経路別

  • 経口
  • 非経口

第11章 市場区分:化学療法別

  • 一次治療
  • 二次治療

第12章 市場促進要因

第13章 促進要因の影響

第14章 市場の課題

第15章 促進要因と課題の影響

第16章 市場動向

第17章 ベンダー情勢

  • 競合シナリオ
  • 市場シェア分析
  • その他の有力ベンダー
  • Amgen

第18章 主要ベンダー分析

  • Bayer HealthCare
  • Bristol-Myers Squibb
  • 中外製薬
  • Merck
  • Sanofi

第19章 付録

  • 略語リスト

第20章 Technavioについて

図表

目次
Product Code: IRTNTR7888

About colorectal cancer

Colorectal cancer refers to malignancies that originate in the rectum or the colon. It is also known as bowel cancer. Formation of adenocarcinomas is the most common feature of colorectal cancer. The cancer starts as a polyp in the inner wall of the colon or rectum. These polyps can be benign or malignant. Some of the risk factors that can cause colorectal cancer are lifestyle changes, old age, genetic disorders, family history, and inflammatory bowel disease. Some of the symptoms of colorectal cancer are blood in stool, decrease in appetite, constipation, weight loss, nausea, bloating, and pelvic pain. Colorectal cancer can be classified into four broad stages. Colorectal cancer can be treated using surgical, chemotherapeutic, biologic, and radiation therapies.

Technavio's analysts forecast the colorectal cancer therapeutics market in APAC to grow at a CAGR of 6.32% over the period 2014-2019.

Covered in this report

The report covers the current scenario and the growth prospects of the colorectal cancer therapeutics market in APAC for the period 2015-2019. To calculate the market size, the report considers revenue generated through the sales of various drugs used in the treatment of colorectal cancer. The colorectal cancer therapeutics market in APAC is segmented based on lines of chemotherapy: first-line chemotherapy and second-line chemotherapy.

Technavio's report, Colorectal Cancer Therapeutics Market in APAC 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers APAC; it also covers the landscape of the colorectal cancer therapeutics market in APAC and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

Key regions

  • APAC
  • China
  • Japan

Key vendors

  • Amgen
  • Bayer
  • Bristol-Myers Squibb
  • Chugai Pharmaceuticals
  • Merck
  • Sanofi

Other Prominent Vendors

  • Accord Healthcare
  • Advenchen Laboratories
  • Aeterna Zentaris
  • AstraZeneca
  • AVEO Oncology
  • Bavarian Nordic
  • Biothera
  • Boehringer Ingelheim
  • Boston Biomedical
  • Cancer Prevention Pharmaceuticals
  • Celator Pharmaceuticals
  • Daiichi Sankyo
  • Debiopharm
  • Eisai
  • Eli Lilly
  • EpicentRx
  • GlaxoSmithKline
  • Hutchison Medipharma
  • Immodulon Therapeutics
  • Immunomedics
  • MacroGenics
  • Merrimack Pharmaceuticals
  • MolMed
  • Mologen
  • Morphotek
  • Mylan
  • Nektar Therapeutics
  • Oncothyreon
  • Otsuka Pharmaceutical
  • PledPharma
  • Precision Biologics
  • PsiOxus Therapeutics
  • Sun Pharmaceutical
  • Symphogen
  • Taiho
  • Takeda
  • Teva Pharmaceuticals
  • ThromboGenics
  • Xbiotech
  • Yakult Honsha

Key market driver

  • Increase in aging population
  • For a full, detailed list, view our report

Key market challenge

  • Unknown disease etiology
  • For a full, detailed list, view our report

Key market trend

  • Rise in public awareness
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview
  • Top-vendor offerings
  • Vectibix

PART 03: Product profiles

  • Stivarga
  • Erbitux
  • Xeloda
  • Avastin
  • Zaltrap

PART 04: Market research methodology

  • Research methodology
  • Economic indicators

PART 05: Introduction

  • Key market highlights

PART 06: Disease overview

  • Understanding the disease
  • High risk factors
  • Signs and symptoms
  • Pathophysiology
  • Diagnosis
  • Staging
  • Biomarker testing
  • Epidemiology
  • Treatment

PART 07: Pipeline portfolio

  • Information on pipeline candidates

PART 08: Market landscape

  • Market overview
  • Market size and forecast
  • Colorectal cancer therapeutics market in Japan
  • Colorectal cancer therapeutics market in China
  • Five forces analysis

PART 09: Market segmentation by based on the type of molecules

  • Small molecules
  • Biologics

PART 10: Market segmentation by route of administration

  • Oral
  • Parenteral

PART 11: Market segmentation by lines of chemotherapy

  • First-line chemotherapy
  • Second-line chemotherapy

PART 12: Market drivers

PART 13: Impact of drivers

PART 14: Market challenges

PART 15: Impact of drivers and challenges

PART 16: Market trends

PART 17: Vendor landscape

  • Competitive scenario
  • Market share analysis 2014
  • Other prominent vendors
  • Amgen

PART 18: Key vendor analysis

  • Bayer HealthCare
  • Bristol-Myers Squibb
  • Chugai Pharmaceutical
  • Merck
  • Sanofi

PART 19: Appendix

  • List of abbreviations

PART 20: Explore Technavio

List of Exhibits

  • Exhibit 01: Product offerings
  • Exhibit 02: High risk factors for colorectal cancer
  • Exhibit 03: Signs and symptoms of colorectal cancer
  • Exhibit 04: Diagnostic tests for colorectal cancer
  • Exhibit 05: Staging for colon cancer
  • Exhibit 06: Staging for rectal cancer
  • Exhibit 07: Types of genes
  • Exhibit 08: Estimated incidence, mortality, and five-year prevalence per 100,000 in APAC 2012
  • Exhibit 09: Colorectal cancer mortality rates in APAC 2012 (rate per 100,000 population)
  • Exhibit 10: Incidence rates of colorectal cancer in Asia, 2011 (rate per 100,000 population)
  • Exhibit 11: Estimated incidence in adult population in APAC 2012
  • Exhibit 12: Colorectal cancer incidence and mortality rates in top seven countries in Asia regions, 2008, males
  • Exhibit 13: Colorectal cancer incidence and mortality rates in top seven countries in Asia regions, 2008, females
  • Exhibit 14: Treatment options for colorectal cancer
  • Exhibit 15: Types of surgical procedure for colorectal cancer
  • Exhibit 16: Types of radiation therapy for colorectal cancer
  • Exhibit 17: Types of targeted therapy
  • Exhibit 18: Summary of approved cancer drugs for colon cancer
  • Exhibit 19: Pipeline molecules for colorectal cancer
  • Exhibit 20: Colorectal cancer therapeutics market in APAC ($ billions)
  • Exhibit 21: Colorectal cancer therapeutics market in Japan 2014-2019 ($ billions)
  • Exhibit 22: Colorectal cancer therapeutics market in China 2014-2019 ($ millions)
  • Exhibit 23: Five forces analysis
  • Exhibit 24: Colorectal cancer therapeutics market in APAC segmented by molecule type
  • Exhibit 25: Colorectal cancer therapeutics market in APAC segmented by route of administration
  • Exhibit 26: Summary of chemotherapy drugs for the treatment of colorectal cancer
  • Exhibit 27: Use of branded targeted therapies in China and Japan 2013
  • Exhibit 28: Drivers of colorectal cancer therapeutics market in APAC
  • Exhibit 29: Impact of drivers
  • Exhibit 30: Challenges of colorectal cancer therapeutics market in APAC
  • Exhibit 31: Impact of drivers and challenges
  • Exhibit 32: Trends of colorectal cancer therapeutics market in APAC
  • Exhibit 33: Vectibix: YoY revenue and growth rate in Japan 2011-2013 ($ millions)
  • Exhibit 34: Amgen: Key takeaways
  • Exhibit 35: Bayer: Key takeaways
  • Exhibit 36: Bristol-Myers Squibb: Key takeaways
  • Exhibit 37: Avastin: YoY revenue and growth rate in Japan 2010-2014 ($ millions)
  • Exhibit 38: Xeloda: YoY revenue and growth rate in Japan 2010-2014 ($ millions)
  • Exhibit 39: Chugai Pharmaceutical: Key takeaways
  • Exhibit 40: Merck: Key takeaways
  • Exhibit 41: Sanofi: Key takeaways
  • Exhibit 42: Amgen: Business segmentation by revenue 2014
  • Exhibit 43: Amgen: Business segmentation by revenue 2013 and 2014 ($ billions)
  • Exhibit 44: Amgen: Geographical segmentation by revenue 2014
  • Exhibit 45: Bayer HealthCare: Business segmentation by revenue 2014
  • Exhibit 46: Bayer HealthCare: Business segmentation by revenue 2013 and 2014 ($ billions)
  • Exhibit 47: Bayer HealthCare: Geographical segmentation by revenue 2014
  • Exhibit 48: Bristol-Myers Squibb: Products segmentation by revenue FY2014
  • Exhibit 49: Bristol-Myers Squibb: Revenue comparison by product segmentation by FY2013 and FY2014
  • Exhibit 50: Bristol-Myers Squibb: Geographical segmentation by FY2014 ($ millions)
  • Exhibit 51: Bristol-Myers Squibb: Revenue comparison by geographical segment by FY2013 and FY2014 ($ millions)
  • Exhibit 52: Chugai Pharmaceuticals: Business segmentation by revenue 2014 (therapeutics)
  • Exhibit 53: Chugai Pharmaceuticals: Geographical segmentation by revenue 2014
  • Exhibit 54: Merck: Business segmentation by revenue 2014
  • Exhibit 55: Merck: Business segmentation by revenue 2013 and 2014 ($ billions)
  • Exhibit 56: Merck: Geographical segmentation by revenue 2014
  • Exhibit 57: Sanofi: Business segmentation by revenue 2014
  • Exhibit 58: Sanofi: Business segmentation by revenue 2013 and 2014 ($ billions)
  • Exhibit 59: Sanofi: Geographical segmentation by revenue 2014
Back to Top